Structure Therapeutics (NASDAQ:GPCR) Reaches New 52-Week Low - Time to Sell?

Structure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report) shares hit a new 52-week low on Thursday . The stock traded as low as $15.31 and last traded at $16.95, with a volume of 1259016 shares changing hands. The stock had previously closed at $15.79.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. William Blair began coverage on shares of Structure Therapeutics in a research report on Friday, February 28th. They issued an "outperform" rating for the company. HC Wainwright reiterated a "buy" rating and issued a $80.00 target price on shares of Structure Therapeutics in a research note on Thursday, December 19th. JMP Securities restated a "market outperform" rating and set a $91.00 price target on shares of Structure Therapeutics in a research report on Wednesday, December 18th. Finally, Stifel Nicolaus started coverage on Structure Therapeutics in a research report on Wednesday, January 8th. They issued a "buy" rating and a $50.00 price objective on the stock. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $81.29.

Structure Therapeutics Stock Performance

The stock has a market cap of $820.58 million, a PE ratio of -19.34 and a beta of -1.35. The company's 50-day moving average price is $22.75 and its two-hundred day moving average price is $30.17.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share for the quarter, beating analysts' consensus estimates of ($0.23) by $0.01. Equities research analysts forecast that Structure Therapeutics Inc. will post -0.82 earnings per share for the current fiscal year.

Remove Ads

Institutional Trading of Structure Therapeutics

A number of hedge funds have recently bought and sold shares of GPCR. Spire Wealth Management purchased a new position in shares of Structure Therapeutics during the fourth quarter worth approximately $243,000. JPMorgan Chase & Co. raised its position in Structure Therapeutics by 302.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 33,936 shares of the company's stock worth $1,489,000 after purchasing an additional 25,500 shares during the period. Barclays PLC lifted its stake in Structure Therapeutics by 64.5% in the third quarter. Barclays PLC now owns 81,138 shares of the company's stock worth $3,562,000 after purchasing an additional 31,815 shares during the last quarter. Pier Capital LLC boosted its position in Structure Therapeutics by 32.7% during the third quarter. Pier Capital LLC now owns 134,291 shares of the company's stock valued at $5,894,000 after buying an additional 33,087 shares during the period. Finally, Franklin Resources Inc. grew its stake in shares of Structure Therapeutics by 9.4% during the third quarter. Franklin Resources Inc. now owns 706,106 shares of the company's stock valued at $30,991,000 after buying an additional 60,397 shares during the last quarter. Institutional investors own 91.78% of the company's stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.